Motus GI (MOTS) Stock Price, News & Analysis

Company Overview

Motus GI Holdings, Inc. is a clinical-stage medical technology company developing advanced endoscopic solutions for the minimally invasive diagnosis and treatment of gastrointestinal disorders. The company’s platform is designed to improve procedural control, stability and precision during complex therapeutic interventions in the GI tract, such as tissue resection, hemostasis and suturing. By integrating electromechanical instruments into a single-use device, Motus GI aims to enhance clinical efficiency and patient outcomes compared with conventional flexible endoscopes.

The company’s lead product candidate is an electromechanical endoscopy system built around a multifunctional, disposable module that delivers stable instrument control and intuitive maneuverability. The platform incorporates proprietary motorized elements and disposable accessory channels, enabling physicians to perform a broad spectrum of advanced therapeutic procedures through natural orifice access. Motus GI has secured intellectual property covering instrument actuation, device assembly and system control software, and is conducting pre-commercial and clinical validation studies in the United States.

Headquartered in California, Motus GI serves hospitals, ambulatory surgery centers and endoscopy clinics across North America. Its management team brings extensive experience in medical device development, regulatory affairs and commercialization for minimally invasive surgical technologies. The company continues to advance its clinical and regulatory programs, positioning its platform for future market entry in the United States and select international markets.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 8 shs
• Average Volume: 5,050 shs
• Market Capitalization: $1 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MOTS Stock Analysis - Frequently Asked Questions

How were Motus GI's earnings last quarter?

Motus GI Holdings, Inc. (NASDAQ:MOTS) released its earnings results on Friday, November, 12th. The company reported ($30.00) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($30.00). The firm earned $0.14 million during the quarter, compared to analysts' expectations of $0.12 million.

When did Motus GI's stock split?

Shares of Motus GI reverse split before market open on Thursday, November 2nd 2023.The 1-15 reverse split was announced on Wednesday, November 1st 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 1st 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Motus GI IPO?

Motus GI (MOTS) raised $21 million in an initial public offering on Wednesday, February 14th 2018. The company issued 3,500,000 shares at $5.00-$7.00 per share. Piper Jaffray served as the underwriter for the IPO and Oppenheimer & Co. was co-manager.

How do I buy shares of Motus GI?

Shares of MOTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Motus GI own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Motus GI investors own include Inovio Pharmaceuticals (INO), NIO (NIO), Tesla (TSLA), Bionano Genomics (BNGO), Acasti Pharma (ACST) and Pfizer (PFE).

Company Calendar

• Last Earnings: 11/12/2021
• Today: 9/10/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:MOTS
• CIK: 1686850
• Web: www.motusgi.com
• Phone: (954) 541-8000
• Fax: 954-541-8265
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $319 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.74 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 5,769,000
• Free Float: 5,749,000
• Market Cap: $1 thousand
• Optionable: Not Optionable
• Beta: 1.01